EUVIMEDEUVIMED entdecken
Crossref

Gualou xiebai decoction ameliorates cardiorenal syndrome type II by regulation of PI3K/AKT/NF-κB signalling pathway

Ying-Yu Wang, Yang-Yang Liu, Jie Li, Yun-Yun Zhang, Yong-Fang Ding, Yun-Ru Peng

Phytomedicine · 2024-01 · 123 · 155172

DOI: 10.1016/j.phymed.2023.155172 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2024-01. Verfasst von Ying-Yu Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Affliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, PR China; Departme…. Hauptthemen laut MEDLINE: Cardio-Renal Syndrome, Myocardial Infarction, Drugs, Chinese Herbal, Peptide Fragments. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 52 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cardiorenal syndromes type II (CRS2) is a multi-organ ailment that manifests as a combination of cardiac and renal dysfunction, resulting in chronic kidney disease due to chronic cardiac insufficiency. It affects at least 26 million people worldwide, and its prevalence is increasing. Gualou Xiebai Decoction (GXD), a traditional Chinese medicine (TCM) with a rich history of application in the management of coronary artery disease, has been explored for its potential therapeutic benefits in CRS2. Nevertheless, the mechanism by which GXD alleviates CRS2 remains obscure, necessitating further investigation. PURPOSE: The aim of this study was to assess the effects of the ethanolic extract of GXD on CRS2 and to elucidate the underlying mechanism in a rat model of myocardial infarction, offering a potential target for clinical treatment for CRS2. STUDY DESIGN AND METHODS: A rat model of CRS2 was induced by surgical myocardial infarction and treated with GXD for 10 weeks. Cardiac function was assessed using echocardiography, while serum and urine biochemistry were analyzed to evaluate potential cardiac and renal damage. Furthermore, tissue samples were obtained for histological, protein, and genetic investigations. In addition, network pharmacology analysis and molecular docking were utilized to predict the primary active compounds, potential therapeutic targets, and interventional pathways through which GXD could potentially exert its effects on CRS2. Subsequently, these predictions were confirmed in vivo and vitro through various analyses. RESULTS: The current investigation employed echocardiography to exhibit the apparent cardiac remodeling following the induction of myocardial infarction. Damage to the heart and kidneys of CRS2 rats was effectively ameliorated by administration of GXD. The outcomes derived from the analyses of HE and Masson staining indicated that the pathological damage to the heart and kidney tissues of rats in the GXD groups was considerably alleviated. Using network pharmacology analysis, AKT1, IL-6, and TNF-α were identified as plausible therapeutic targets for the treatment of CRS with GXD. Subsequent functional and pathway enrichment analysis of the underlying targets disclosed that the PI3K/AKT/NF-κB signaling pathway may be involved in the mechanism of GXD in the treatment of CRS2. Immunohistochemical, western blot, RT-PCR and immunofluorescence staining were employed to demonstrate that GXD can regulate the PI3K/AKT/NF-κB signaling pathway in the CRS2 rat model. Ultimately, administration of the PI3K/AKT agonist 740Y-P counteracted the effect of diosmetin, which was one of the potential active components of GXD analysed by compound-target-disease network, on p-PI3K and p-AKT in vitro. CONCLUSIONS: The findings of this study suggest that GXD improves cardiac and renal function in CRS2 rats and that the underlying mechanism involves inhibition of the PI3K/AKT/NF-κB pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardio-Renal SyndromeMyocardial InfarctionDrugs, Chinese HerbalPeptide FragmentsReceptors, Platelet-Derived Growth FactorHumansAnimalsRatsNF-kappa BPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktMolecular Docking SimulationSignal Transduction

Stichwörter der Autor:innen

Cardiorenal SyndromeGualou Xiebai DecoctionInflammationNetwork pharmacologyPI3K/AKT/NF-κB signaling pathway

Substanzen

NF-kappa Bgualou xiebai baijiutangPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akt740Y-PDrugs, Chinese HerbalPeptide FragmentsReceptors, Platelet-Derived Growth Factor

Autor:innen und Institutionen

  • Affliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, PR China; Department of Pharmacology and Toxicology, Jiangsu Province Academy of Traditi…

Zitieren

APA

Wang, Y. Y., Liu, Y. Y., Li, J., Zhang, Y. Y., Ding, Y. F., & Peng, Y. R. (2024). Gualou xiebai decoction ameliorates cardiorenal syndrome type II by regulation of PI3K/AKT/NF-κB signalling pathway. Phytomedicine, 123, 155172. https://doi.org/10.1016/j.phymed.2023.155172

Vancouver

Wang YY, Liu YY, Li J, Zhang YY, Ding YF, Peng YR. Gualou xiebai decoction ameliorates cardiorenal syndrome type II by regulation of PI3K/AKT/NF-κB signalling pathway. Phytomedicine. 2024;123:155172. doi:10.1016/j.phymed.2023.155172

BibTeX
@article{Wang2024,
  author = {Wang, Ying-Yu and Liu, Yang-Yang and Li, Jie and Zhang, Yun-Yun and Ding, Yong-Fang and Peng, Yun-Ru},
  title = {Gualou xiebai decoction ameliorates cardiorenal syndrome type II by regulation of PI3K/AKT/NF-κB signalling pathway},
  journal = {Phytomedicine},
  year = {2024},
  volume = {123},
  pages = {155172},
  doi = {10.1016/j.phymed.2023.155172}
}
Kostenlos starten →